Primary Prophylaxis of Bacterial Infections and Pneumocystis Jirovecii Pneumonia in Patients with Hematologic Malignancies and Solid Tumors: 2020 Updated Guidelines of the Infectious Diseases Working Party of the German Society of Hematology And...

Overview

Journal Ann Hematol

Specialty Hematology

Date 2021 Apr 13

PMID 33846857

Citations 30

Authors

Annika Y Classen

Larissa Henze

Marie von Lilienfeld-Toal

Georg Maschmeyer

Michael Sandherr

Luisa Duran Graeff

Nael Alakel

Maximilian Christopeit

Stefan W Krause

Karin Mayer

Silke Neumann

Oliver A Cornely

Olaf Penack

Florian Weissinger

Hans-Heinrich Wolf

Jorg Janne Vehreschild

Affiliations

Soon will be listed here.

Abstract

Hematologic and oncologic patients with chemo- or immunotherapy-related immunosuppression are at substantial risk for bacterial infections and Pneumocystis jirovecii pneumonia (PcP). As bacterial resistances are increasing worldwide and new research reshapes our understanding of the interactions between the human host and bacterial commensals, administration of antibacterial prophylaxis has become a matter of discussion. This guideline constitutes an update of the 2013 published guideline of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO). It gives an overview about current strategies for antibacterial prophylaxis in cancer patients while taking into account the impact of antibacterial prophylaxis on the human microbiome and resistance development. Current literature published from January 2012 to August 2020 was searched and evidence-based recommendations were developed by an expert panel. All recommendations were discussed and approved in a consensus conference of the AGIHO prior to publication. As a result, we present a comprehensive update and extension of our guideline for antibacterial and PcP prophylaxis in cancer patients.

Citing Articles

Current practice of screening and antimicrobial prophylaxis to prevent Gram-negative bacterial infection in high-risk haematology patients: results from a pan-European survey.

Stemler J, Gavriilaki E, Hlukhareva O, Khanna N, Neofytos D, Akova M Ther Adv Infect Dis. 2024; 11:20499361241271863.

PMID: 39493728 PMC: 11528667. DOI: 10.1177/20499361241271863.

Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial.

Harbeck N, Ciruelos E, Jerusalem G, Muller V, Niikura N, Viale G Nat Med. 2024; 30(12):3717-3727.

PMID: 39271844 PMC: 11645283. DOI: 10.1038/s41591-024-03261-7.

Guidelines for Antibiotics Prescription in Critically Ill Patients.

Khilnani G, Tiwari P, Mittal S, Kulkarni A, Chaudhry D, Zirpe K Indian J Crit Care Med. 2024; 28(Suppl 2):S104-S216.

PMID: 39234229 PMC: 11369928. DOI: 10.5005/jp-journals-10071-24677.

Cutaneous Infection in an Allogeneic Stem Cell Transplant Recipient.

Sood N, Vadnerkar A, Kodali M, Hamacher L Eur J Case Rep Intern Med. 2024; 11(7):004615.

PMID: 38984179 PMC: 11229477. DOI: 10.12890/2024_004615.

Pneumonia in HIV-Negative, Non-transplant Patients: Epidemiology, Clinical Manifestations, Diagnosis, Treatment, and Prevention.

Rhoads S, Maloney J, Mantha A, Van Hook R, Henao-Martinez A Curr Fungal Infect Rep. 2024; 18(2):125-135.

PMID: 38948111 PMC: 11213562. DOI: 10.1007/s12281-024-00482-8.

References

Kuderer N, Dale D, Crawford J, Cosler L, Lyman G . Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer. 2006; 106(10):2258-66. DOI: 10.1002/cncr.21847. View

Pagano L, Caira M, Tumbarello M, Fanci R, Garzia M, Vianelli N . A prospective survey of febrile events in hematological malignancies. Ann Hematol. 2011; 91(5):767-774. DOI: 10.1007/s00277-011-1373-2. View

Cordonnier C, Cesaro S, Maschmeyer G, Einsele H, Donnelly J, Alanio A . Pneumocystis jirovecii pneumonia: still a concern in patients with haematological malignancies and stem cell transplant recipients. J Antimicrob Chemother. 2016; 71(9):2379-85. DOI: 10.1093/jac/dkw155. View

Bucaneve G, Micozzi A, Menichetti F, Martino P, Dionisi M, Martinelli G . Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med. 2005; 353(10):977-87. DOI: 10.1056/NEJMoa044097. View

Cullen M, Steven N, Billingham L, Gaunt C, Hastings M, Simmonds P . Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med. 2005; 353(10):988-98. DOI: 10.1056/NEJMoa050078. View

Hidalgo M, Mendiola C, Lopez-Vega J, Castellano D, Mendez M, Lopez-Brea M . A multicenter randomized Phase II trial of granulocyte-colony stimulating factor-supported, platinum-based chemotherapy with flexible midcycle cisplatin administration in patients with advanced ovarian carcinoma. PSAMOMA Cooperative Group, Spain. Cancer. 1998; 83(4):719-25. DOI: 10.1002/(sici)1097-0142(19980815)83:4<719::aid-cncr13>3.0.co;2-v. View

Heil G, Hoelzer D, Sanz M, Lechner K, Liu Yin J, Papa G . A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. The International Acute Myeloid Leukemia Study Group. Blood. 1998; 90(12):4710-8. View

Truong J, Lee E, Trudeau M, Chan K . Interpreting febrile neutropenia rates from randomized, controlled trials for consideration of primary prophylaxis in the real world: a systematic review and meta-analysis. Ann Oncol. 2015; 27(4):608-18. DOI: 10.1093/annonc/mdv619. View

Liss B, Vehreschild J, Cornely O, Hallek M, Fatkenheuer G, Wisplinghoff H . Intestinal colonisation and blood stream infections due to vancomycin-resistant enterococci (VRE) and extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBLE) in patients with haematological and oncological malignancies. Infection. 2012; 40(6):613-9. DOI: 10.1007/s15010-012-0269-y. View

10.

Vehreschild J, Bohme A, Cornely O, Kahl C, Karthaus M, Kreuzer K . Prophylaxis of infectious complications with colony-stimulating factors in adult cancer patients undergoing chemotherapy-evidence-based guidelines from the Infectious Diseases Working Party AGIHO of the German Society for Haematology and Medical.... Ann Oncol. 2014; 25(9):1709-1718. DOI: 10.1093/annonc/mdu035. View

11.

Neumann S, Krause S, Maschmeyer G, Schiel X, von Lilienfeld-Toal M . Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematological malignancies and solid tumors : guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and.... Ann Hematol. 2013; 92(4):433-42. PMC: 3590398. DOI: 10.1007/s00277-013-1698-0. View

12.

Cornely O, Cuenca-Estrella M, Meis J, Ullmann A . European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Fungal Infection Study Group (EFISG) and European Confederation of Medical Mycology (ECMM) 2013 joint guidelines on diagnosis and management of rare and emerging fungal.... Clin Microbiol Infect. 2014; 20 Suppl 3:1-4. DOI: 10.1111/1469-0691.12569. View

13.

Ullmann A, Schmidt-Hieber M, Bertz H, Heinz W, Kiehl M, Kruger W . Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016. Ann Hematol. 2016; 95(9):1435-55. PMC: 4972852. DOI: 10.1007/s00277-016-2711-1. View

14.

Sandherr M, Hentrich M, von Lilienfeld-Toal M, Massenkeil G, Neumann S, Penack O . Antiviral prophylaxis in patients with solid tumours and haematological malignancies--update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO). Ann Hematol. 2015; 94(9):1441-50. PMC: 4525190. DOI: 10.1007/s00277-015-2447-3. View

15.

Slavin M, Lingaratnam S, Mileshkin L, Booth D, Cain M, Ritchie D . Use of antibacterial prophylaxis for patients with neutropenia. Australian Consensus Guidelines 2011 Steering Committee. Intern Med J. 2011; 41(1b):102-9. DOI: 10.1111/j.1445-5994.2010.02341.x. View

16.

Taplitz R, Kennedy E, Bow E, Crews J, Gleason C, Hawley D . Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update. J Clin Oncol. 2018; 36(30):3043-3054. DOI: 10.1200/JCO.18.00374. View

17.

Chao C, Page J, Yang S, Rodriguez R, Huynh J, Chia V . History of chronic comorbidity and risk of chemotherapy-induced febrile neutropenia in cancer patients not receiving G-CSF prophylaxis. Ann Oncol. 2014; 25(9):1821-1829. DOI: 10.1093/annonc/mdu203. View

18.

Lyman G, Abella E, Pettengell R . Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: A systematic review. Crit Rev Oncol Hematol. 2014; 90(3):190-9. DOI: 10.1016/j.critrevonc.2013.12.006. View

19.

Klastersky J, de Naurois J, Rolston K, Rapoport B, Maschmeyer G, Aapro M . Management of febrile neutropaenia: ESMO Clinical Practice Guidelines. Ann Oncol. 2016; 27(suppl 5):v111-v118. DOI: 10.1093/annonc/mdw325. View

20.

Flowers C, Seidenfeld J, Bow E, Karten C, Gleason C, Hawley D . Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2013; 31(6):794-810. DOI: 10.1200/JCO.2012.45.8661. View